Akiko Chiba1, Tanya L Hoskin2, Courtney N Heins2, Kelly K Hunt3,4, Elizabeth B Habermann1,2,5, Judy C Boughey6,7. 1. Department of Surgery, Mayo Clinic, Rochester, MN, USA. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 4. American College of Surgeons Clinical Research Program and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. 5. Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 6. Department of Surgery, Mayo Clinic, Rochester, MN, USA. boughey.judy@mayo.edu. 7. American College of Surgeons Clinical Research Program and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. boughey.judy@mayo.edu.
Abstract
BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. METHODS: Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age ≥50 years from 2004 to 2012. The time intervals of pre-Z1031 (2004-2006), during Z1031 (2007-2009), and post-Z1031 (2010-2012) were examined, and adjusted analyses were performed using multivariable logistic regression. RESULTS: Of 77,272 patients, 2294 (3.0 %) received NET. Clinical T-stage distribution was 66,885 (86.6 %) for cT2, 7318 (9.5 %) for cT3, and 3069 (4.0 %) for cT4a-c. A small but statistically significant increase in NET use was noted, from 2.7 % pre-Z1031 to 3.2 % post-Z1031; the adjusted odds ratio (OR) for NET was 1.28 [95 % confidence interval (CI) 1.13-1.45; p < 0.001] for post-Z1031 versus pre-Z1031. NET use varied by clinical T stage, increasing from 1.8 % pre-Z1031 to 2.4 % post-Z1031 in cT2 patients (p < 0.001) and from 6.3 % pre-Z1031 to 7.4 % post-Z1031 in cT3 patients (p = 0.02). Patients receiving NET were more likely to undergo BCS compared with patients undergoing primary surgery (46.4 vs. 43.9 %; p = 0.02) with an adjusted OR of 1.60 (95 % CI 1.46-1.75; p < 0.001). CONCLUSIONS: NET use has increased slowly since the Z1031 trial; however, overall use remains low. NET significantly increased the rates of BCS in patients with HR-positive clinical T2-4c breast cancer. Clinicians should consider NET use for patients with HR-positive breast cancer interested in BCS.
BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. METHODS: Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancerpatients age ≥50 years from 2004 to 2012. The time intervals of pre-Z1031 (2004-2006), during Z1031 (2007-2009), and post-Z1031 (2010-2012) were examined, and adjusted analyses were performed using multivariable logistic regression. RESULTS: Of 77,272 patients, 2294 (3.0 %) received NET. Clinical T-stage distribution was 66,885 (86.6 %) for cT2, 7318 (9.5 %) for cT3, and 3069 (4.0 %) for cT4a-c. A small but statistically significant increase in NET use was noted, from 2.7 % pre-Z1031 to 3.2 % post-Z1031; the adjusted odds ratio (OR) for NET was 1.28 [95 % confidence interval (CI) 1.13-1.45; p < 0.001] for post-Z1031 versus pre-Z1031. NET use varied by clinical T stage, increasing from 1.8 % pre-Z1031 to 2.4 % post-Z1031 in cT2patients (p < 0.001) and from 6.3 % pre-Z1031 to 7.4 % post-Z1031 in cT3patients (p = 0.02). Patients receiving NET were more likely to undergo BCS compared with patients undergoing primary surgery (46.4 vs. 43.9 %; p = 0.02) with an adjusted OR of 1.60 (95 % CI 1.46-1.75; p < 0.001). CONCLUSIONS: NET use has increased slowly since the Z1031 trial; however, overall use remains low. NET significantly increased the rates of BCS in patients with HR-positive clinical T2-4c breast cancer. Clinicians should consider NET use for patients with HR-positive breast cancer interested in BCS.
Authors: Ian E Smith; Mitch Dowsett; Stephen R Ebbs; J Michael Dixon; Anthony Skene; J-U Blohmer; Susan E Ashley; Stephen Francis; Irene Boeddinghaus; Geraldine Walsh Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544
Authors: W Eiermann; S Paepke; J Appfelstaedt; A Llombart-Cussac; J Eremin; J Vinholes; L Mauriac; M Ellis; M Lassus; H A Chaudri-Ross; M Dugan; M Borgs Journal: Ann Oncol Date: 2001-11 Impact factor: 32.976
Authors: M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: Manfred Kaufmann; Gunter von Minckwitz; Elefhterios P Mamounas; David Cameron; Lisa A Carey; Massimo Cristofanilli; Carsten Denkert; Wolfgang Eiermann; Michael Gnant; Jay R Harris; Thomas Karn; Cornelia Liedtke; Davide Mauri; Roman Rouzier; Eugen Ruckhaeberle; Vladimir Semiglazov; W Fraser Symmans; Andrew Tutt; Lajos Pusztai Journal: Ann Surg Oncol Date: 2011-12-23 Impact factor: 5.344
Authors: Matthew J Ellis; Vera J Suman; Jeremy Hoog; Li Lin; Jacqueline Snider; Aleix Prat; Joel S Parker; Jingqin Luo; Katherine DeSchryver; D Craig Allred; Laura J Esserman; Gary W Unzeitig; Julie Margenthaler; Gildy V Babiera; P Kelly Marcom; Joseph M Guenther; Mark A Watson; Marilyn Leitch; Kelly Hunt; John A Olson Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: C Abrial; M-A Mouret-Reynier; H Curé; V Feillel; M Leheurteur; S Lemery; G Le Bouëdec; X Durando; J Dauplat; P Chollet Journal: Breast Date: 2005-10-17 Impact factor: 4.380
Authors: Marco Colleoni; Vincenzo Bagnardi; Nicole Rotmensz; Richard D Gelber; Giuseppe Viale; Giancarlo Pruneri; Paolo Veronesi; Rosalba Torrisi; Anna Cardillo; Emilia Montagna; Elisabetta Campagnoli; Alberto Luini; Mattia Intra; Viviana Galimberti; Eloise Scarano; Giulia Peruzzotti; Aron Goldhirsch Journal: Breast Cancer Res Treat Date: 2008-10-22 Impact factor: 4.872
Authors: Harry D Bear; Wen Wan; André Robidoux; Peter Rubin; Steven Limentani; Richard L White; James Granfortuna; Judith O Hopkins; Dwight Oldham; Angel Rodriguez; Amy P Sing Journal: J Surg Oncol Date: 2017-04-13 Impact factor: 3.454
Authors: Tal Sella; Shari I Gelber; Philip D Poorvu; Hee-Jeong Kim; Laura Dominici; Yaileen D Guzman-Arocho; Laura Collins; Kathryn J Ruddy; Rulla M Tamimi; Jeffrey M Peppercorn; Lidia Schapira; Virginia F Borges; Steven E Come; Ellen Warner; Craig Snow; Debbie M Jakubowski; Christy A Russell; Eric P Winer; Shoshana M Rosenberg; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2020-11-04 Impact factor: 4.872
Authors: Macy M Goldbach; Laura Burkbauer; Tina Bharani; Austin D Williams; Luke Keele; Jami Rothman; Rachel Jankowitz; Julia C Tchou Journal: Ann Surg Oncol Date: 2021-06-14 Impact factor: 5.344
Authors: Max Aa Ragusi; Gonneke Ao Winter-Warnars; Jelle Wesseling; Sabine C Linn; Regina G Beets-Tan; Bas Hm van der Velden; Sjoerd G Elias; Kenneth Ga Gilhuijs; Claudette E Loo Journal: Br J Radiol Date: 2021-07-01 Impact factor: 3.039